Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.
Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.
I’m just going off the information that my health care provider gave me. She said they only use it on high risk individuals because it’s not as effective as claimed.
Might want to find a new health care provider.
She may be taking you for a ride.